Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.
about
Aminoadamantanes versus other antiviral drugs for chronic hepatitis CAminoadamantanes for chronic hepatitis CNitazoxanide for chronic hepatitis CPeginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis CVitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirinTherapeutic issues in HIV/HCV-coinfected patientsA study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patientsAntiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated conditionWeight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatmentUse of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitisL-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin.Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy.German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients.Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevirLong-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled studyWomen experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis.Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapyThe practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections.Management of Adverse Events During the Treatment of Chronic Hepatitis C Infection.Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.Hepatitis C treatment completion rates in routine clinical care.Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C InfectionEffect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord.Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study.Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus.Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1.Definition and management of anemia in patients infected with hepatitis C virus.Issues in designing and interpreting clinical trials of treatments for chronic hepatitis C.Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin.Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy.Racial differences in hepatitis C treatment eligibility.Ribavirin in the treatment of chronic hepatitis C.Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin.Hepatitis C comorbidities affecting the course and response to therapyAntiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection.Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.Taribavirin in the treatment of hepatitis C.
P2860
Q24193940-43D01A03-02EE-4344-900D-64F2E6C213F0Q24194770-9EB9956A-F5C3-4538-93A7-4A3C4965A18DQ24197485-17266AF5-CAAC-4EC7-8C41-973E6353F7F8Q24200189-030CBA8B-A3DC-4A2C-8018-A9BD1EF80047Q26784321-731232C0-A62D-4063-B4C3-754A82D524ADQ27481053-DF3EC3DF-FDEB-4689-8019-F5F7A90E3570Q27487985-11741D90-0DB9-4B02-AC9E-F1F65DDC33F7Q27490340-25975E5B-67E7-4B7E-878B-C08DF461530EQ27490841-9806EB81-FFC1-4EC4-ADA6-669AF4EE399AQ33394544-317BF71E-C620-41EA-83A3-4F527E4FAD3CQ33398403-D5FE56F5-432E-40D1-AF23-E673609F82A9Q33815550-7EE0500E-3DDC-4F2F-A3D8-A8317F5D2CFFQ33863006-D0C46FA1-E01C-4CF2-94CB-40AAC0BA0F81Q34078331-2834278F-0078-4384-B005-5DA142F13A29Q34146792-52284D99-35D2-4EAA-84F3-EC1E79B981A6Q34148055-2F513AF1-4CC3-4E1D-9127-135CC351B5C7Q34246440-16EB6D6B-7A5F-4A31-8109-BED1184721A0Q34996746-353A9B37-C784-4C11-8E40-0C02272499E1Q35073553-7DD88669-C90F-496E-96D7-BEF4A28A5865Q35082620-5BC1C1A1-92F0-45FE-9003-C5412D2C772FQ35088160-1C253BA1-CB13-4E75-A2A2-2AFDFF2E54ABQ35093134-1263982B-4F57-44A0-9DDB-695B21C637E7Q35764202-414268DD-F2ED-442B-B2A3-331F5170EF2AQ35832820-76AEBDB6-5D55-49B8-AE20-4C436FA1DD4AQ36018931-F631ADA1-6E53-4BBC-8E6E-D876A62A70C7Q36073408-56B67642-711D-4118-BC2C-2BF6A8A6EB07Q36146443-F08182F7-215E-456E-8B8B-6635F2B2F81AQ36255875-FA83E0E8-86E9-4C84-9934-3C6589CDCF98Q36382719-0DF7571C-47FD-42C4-A492-FF7CAB6B04BCQ36455842-BC915ECA-F025-4FC8-A41A-17A9B74FD1EFQ36455986-2A6F0DD1-4F96-4816-A716-05E0B7F1E09BQ36542793-42333C45-1201-4160-8CAB-6A53F0D0995CQ36775650-71FF5D6C-A605-4E55-8D25-B2C6C4D33803Q37077462-262B909C-7815-43FC-85F3-E7FD4CB0B807Q37195248-DB9D244E-9BD6-4CBD-8D05-BC44B6079EF4Q37364301-19665EBA-C169-4B90-AA02-76C3DC157AC4Q37402438-191D0C0D-E47A-48F2-BFA5-A23DCC261580Q37534731-72C3D311-4128-4FDE-B3AF-E1E67D47DAC6Q37851006-B751A7F9-D123-4076-AA58-F3A370D4FB38Q37919889-6F9EFAA0-6413-4C1D-9410-159CBD2B5DF4
P2860
Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Changes in haemoglobin during ...... c hepatitis C virus infection.
@en
Changes in haemoglobin during ...... c hepatitis C virus infection.
@nl
type
label
Changes in haemoglobin during ...... c hepatitis C virus infection.
@en
Changes in haemoglobin during ...... c hepatitis C virus infection.
@nl
prefLabel
Changes in haemoglobin during ...... c hepatitis C virus infection.
@en
Changes in haemoglobin during ...... c hepatitis C virus infection.
@nl
P2093
P2860
P1476
Changes in haemoglobin during ...... ic hepatitis C virus infection
@en
P2093
P2860
P304
P356
10.1111/J.1365-2893.2004.00490.X
P50
P577
2004-05-01T00:00:00Z